KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system
Open Access
- 9 October 2017
- journal article
- research article
- Published by IOS Press in Tumor Biology
- Vol. 39 (10)
- https://doi.org/10.1177/1010428317733984
Abstract
Epithelial ovarian neoplasms are a heterogeneous group of tumors, including various malignancies with distinct clinicopathologic and molecular features. Mutations in BRAF and KRAS genes are the most frequent genetic aberrations found in low-grade serous ovarian carcinomas and serous and mucinous borderline tumors. Implementation of targeted therapeutic strategies requires access to highly specific and highly sensitive diagnostic tests for rapid determination of mutation status. One candidate for such test is fully integrated, real-time polymerase chain reaction–based Idylla™ system for quick and simple detection of KRAS mutations in formaldehyde fixed-paraffin embedded tumor samples. The primary aim of this study was to verify whether fully integrated real-time polymerase chain reaction–based Idylla system may be useful in determination of KRAS mutation status in patients with borderline ovarian tumors and low-grade ovarian carcinomas. The study included tissue specimens from 37 patients with histopathologically verified ovarian masses, operated on at the Department of Obstetrics and Gynecology, Nicolaus Copernicus University Collegium Medicum in Bydgoszcz (Poland) between January 2009 and June 2012. Based on histopathological examination of surgical specimens, 30 lesions were classified as low-grade ovarian carcinomas and 7 as borderline ovarian tumors. Seven patients examined with Idylla KRAS Mutation Test tested positive for KRAS mutation. No statistically significant association was found between the incidence of KRAS mutations and histopathological type of ovarian tumors. Mean survival of the study subjects was 48.51 months (range 3–60 months). Presence of KRAS mutation did not exert a significant effect on the duration of survival in our series. Our findings suggest that Idylla KRAS Mutation Test may be a useful tool for rapid detection of KRAS mutations in ovarian tumor tissue.Keywords
This publication has 38 references indexed in Scilit:
- Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal CancerPLOS ONE, 2016
- KRAS/BRAF Analysis in Ovarian Low-Grade Serous Carcinoma Having Synchronous All Pathological Precursor RegionsInternational Journal of Molecular Sciences, 2016
- Genetic and molecular changes in ovarian cancerCancer Biology & Medicine, 2016
- BRAF Mutation is associated with early stage disease and improved outcome in patients with low‐grade serous ovarian cancerCancer, 2012
- Reclassification of serous ovarian carcinoma by a 2‐tier systemCancer, 2011
- Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigmHuman Pathology, 2011
- Oncogenic K-RAS subverts the antiapoptotic role of N-RAS and alters modulation of the N-RAS: gelsolin complexOncogene, 2006
- In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low‐grade serous tumoursThe Journal of Pathology, 2004
- Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous CarcinomaJNCI Journal of the National Cancer Institute, 2003
- Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactionsBiochemical Journal, 2000